1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11):1905-1917.
2. Shelton RC: What are the comparative benefits and harms of augmentation treatments in major depression? J Clin Psychiatry 2015, 76(4):e531-533.
3. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH: Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry 2016, 173(6):575-587.
4. Sarris J, Kavanagh DJ, Byrne G: Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2010, 44(1):32-41.
5. Luna RA, Foster JA: Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression. Curr Opin Biotechnol 2015, 32:35-41.
6. Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF, Stanton C: Gut microbiota, obesity and diabetes. Postgrad Med J 2016, 92(1087):286-300.
7. Cryan JF, Dinan TG: Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012, 13(10):701-712.
8. Lima-Ojeda JM, Rupprecht R, Baghai TC: "I Am I and My Bacterial Circumstances": Linking Gut Microbiome, Neurodevelopment, and Depression. Front Psychiatry 2017, 8:153.
9. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S: Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011, 108(7):3047-3052.
10. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF: Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011, 108(38):16050-16055.
11. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, Zeng L, Chen J, Fan S, Du X et al: Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry 2016, 21(6):786-796.
12. Schroeder FA, Lin CL, Crusio WE, Akbarian S: Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007, 62(1):55-64.
13. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y: Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004, 558(Pt 1):263-275.
14. Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linløkken A, Wilson R, Rudi K: Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil 2014, 26(8):1155-1162.
15. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J et al: Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015, 48:186-194.
16. Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ: Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. J Neurogastroenterol Motil 2016, 22(2):201-212.
17. Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF: The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv Exp Med Biol 2014, 817:373-403.
18. Schmidt C: Mental health: thinking from the gut. Nature 2015, 518(7540):S12-15.
19. Maes M: The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29(3):287-291.
20. Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E: In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 2013, 127(5):344-354.
21. Maes M, Kubera M, Leunis JC, Berk M: Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012, 141(1):55-62.
22. El Aidy S, Dinan TG, Cryan JF: Immune modulation of the brain-gut-microbe axis. Front Microbiol 2014, 5:146.
23. Dinan TG, Cryan JF: The impact of gut microbiota on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care 2015, 18(6):552-558.
24. Sampson TR, Mazmanian SK: Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015, 17(5):565-576.
25. Sherwin E, Rea K, Dinan TG, Cryan JF: A gut (microbiome) feeling about the brain. Curr Opin Gastroenterol 2016, 32(2):96-102.
26. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY: Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015, 161(2):264-276.
27. Savignac HM, Corona G, Mills H, Chen L, Spencer JP, Tzortzis G, Burnet PW: Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem Int 2013, 63(8):756-764.
28. Shi SS, Shao SH, Yuan BP, Pan F, Li ZL: Acute stress and chronic stress change brain-derived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus. Yonsei Med J 2010, 51(5):661-671.
29. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C: Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 2010, 44(13):808-816.
30. Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, Cichocki M: Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 2009, 61(6):1017-1023.
31. Gersner R, Toth E, Isserles M, Zangen A: Site-specific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Biol Psychiatry 2010, 67(2):125-132.
32. Dinan TG, Stanton C, Cryan JF: Psychobiotics: a novel class of psychotropic. Biol Psychiatry 2013, 74(10):720-726.
33. Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, Houdeau E, Fioramonti J, Bueno L, Theodorou V: Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 2012, 37(11):1885-1895.
34. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA et al: Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505(7484):559-563.
35. Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S: Nutritional aspects of depression. Cell Physiol Biochem 2015, 37(3):1029-1043.
36. Lang UE, Borgwardt S: Molecular mechanisms of depression: perspectives on new treatment strategies. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2013, 31(6):761-777.
37. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T et al: Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2015, 2(3):271-274.
38. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M et al: Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011, 105(5):755-764.
39. Marotta A, Sarno E, Del Casale A, Pane M, Mogna L, Amoruso A, Felis GE, Fiorio M: Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality. Front Psychiatry 2019, 10:164.
40. Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS: A meta-analysis of the use of probiotics to alleviate depressive symptoms. J Affect Disord 2018, 228:13-19.
41. Neufeld KM, Kang N, Bienenstock J, Foster JA: Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2011, 23(3):255-264, e119.
42. Scott LV, Clarke G, Dinan TG: The brain-gut axis: a target for treating stress-related disorders. Mod Trends Pharmacopsychiatri 2013, 28:90-99.
43. Logan AC, Katzman M: Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses 2005, 64(3):533-538.
44. Vlainić JV, Šuran J, Vlainić T, Vukorep AL: Probiotics as an Adjuvant Therapy in Major Depressive Disorder. Curr Neuropharmacol 2016, 14(8):952-958.
45. Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, Nunes E, Deliyannides D, Agosti V, Donovan SJ, Petkova E et al: Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 1996, 53(9):785-792.
46. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F et al: When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003, 160(4):734-740.
47. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K: Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 2013, 150(2):384-388.
48. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D: SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet 2013, 381(9861):91-92.
49. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB et al: Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell 2018, 174(6):1388-1405.e1321.
50. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A: Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition 2016, 32(3):315-320.
51. Depression: Management of Depression in Primary and Secondary Care. Clinical Practice Guideline Number 23. In. London: National Collaborating Centre for Mental Health - National Institute for Clinical Excellence; 2004.
52. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
53. Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K: Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr 2019, 38(2):522-528.
54. Bzdok D, Meyer-Lindenberg A: Machine Learning for Precision Psychiatry: Opportunities and Challenges. Biol Psychiatry Cogn Neurosci Neuroimaging 2018, 3(3):223-230.
55. Dwyer DB, Falkai P, Koutsouleris N: Machine Learning Approaches for Clinical Psychology and Psychiatry. Annu Rev Clin Psychol 2018, 14:91-118.
56. Insel TR: The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry 2014, 171(4):395-397.
57. Insel TR, Cuthbert BN: Medicine. Brain disorders? Precisely. Science 2015, 348(6234):499-500.
58. Insel TR, Charney DS: Research on major depression: strategies and priorities. JAMA 2003, 289(23):3167-3168.
59. Lingam R, Scott J: Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002, 105(3):164-172.
60. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, Schiweck C, Kurilshikov A, Joossens M, Wijmenga C et al: The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019, 4(4):623-632.
61. Jacka FN: Nutritional Psychiatry: Where to Next? EBioMedicine 2017, 17:24-29.
62. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6(4):278-296.
63. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.